Skip to Content
Søk Menu
16. – 18. FEBRUAR 2023

ASCO GU 2023 | Genitourinary Cancers Symposium

Seneste nytt fra ASCO GU 2023

Inverse correlation between natural killer cell and treatment with enzalutamide

  • / Ahmed H. Zedan
Simon Crabb

CAPItello-280 trial aims to confirm findings from ProCAID trial.

/ Simon Crabb
ProstatakreftASCOGU23 Play the Video
Aristotle Bamias

IMvigor130: Final overall survival (OS) analysis of atezolizumab with/without chemotherapy

/ Aristotle Bamias
ASCOGU23 Play the Video

New improvement of PFS in first-line treatment of advanced Renal-Cell carcinoma

/ BestPractice Nordic
NyrekreftASCOGU23

Darolutamide – A viable long-term treatment for nmCRPC

/ BestPractice Nordic
ProstatakreftASCOGU23

ASCO GU 2022

New potential first-line therapy for patients with mCR-prostate cancer and HRR-alterations

  • / Kim Nguyen Chi

BestPractice Nordic inviterer til debattmøte

Få på dette debattmøte d. 17.mars 2022, svar på om utfordringene for Nye metoder er løst, når vi perspektiverer på rapporten Evaluering av systemet for Nye metoder i spesialisthelsetjenesten.

Tilmeld nu

Bone mineral density in patients with castration-sensitive prostate cancer treated with abiraterone

/ Guilhem Roubaud
ProstatakreftASCOGU22 Play the Video
Kim Nguyen Chi

New potential first-line therapy for patients with mCR-prostate cancer and HRR-alterations

/ Kim Nguyen Chi
ProstatakreftASCOGU22 Play the Video
Redas Trepiakas

CYCLONE 2: Abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer

/ Redas Trepiakas
ProstatakreftASCOGU22 Play the Video
Load more

Innhold fra tidligere dekning

Management of Erdafitinib, a pan-FGFR kinase inhibitor, treatment-emergent adverse events

/ Arlene O. Siefker-Radtke
BlærekreftASCOGU21 Play the Video

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with first-line nivolumab plus cabozantinib

/ David Cella
NyrekreftASCOGU21 Play the Video

Comorbidity leads to poorer survival in patients with renal cell carcinoma in Danish cohort study

/ BestPractice Nordic
NyrekreftASCOGU21

Final analysis of TITAN confirms survival benefit of apalutamide for metastatic castration-sensitive prostate cancer

/ BestPractice Nordic
ProstatakreftASCOGU21
Mere indhold fra ASCO 2021

Back to top